Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies

Improved Outcomes in Mcrpc With Psma-directed Diagnostics and Therapies is organized by ReachMD.

Release Date: 08/31/2022
Expiration Date: 08/31/2023

Description :
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).

Learning Objectives :
At the conclusion of this activity, participants should be better able to:
• Describe the clinical significance of the background and use of PSMA-based imaging for PET/CT for the diagnosis of mCRPC
• Evaluate clinical trial data and research findings in the determination of best-practice selection and sequencing of available and emerging treatment modalities for patients with mCRPC
• Recognize the potential application of both PSMA-directed PET for diagnostics and PSMA-directed RLT for treatment
• Identify the patients who may benefit from a theranostic approach to slow tumor progression|
• Apply strategies to identify and manage adverse events associated with investigative emerging therapies for mCRPC
• Summarize the potential impact of QoL improvements and other clinical challenges in patients with heavily pretreated mCRPC